Home Featured Page 201

Featured

Latest

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin...

Manvir Singh: Shamanism, the Timeless Religion

2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: 10 Standout Stories in Psychedelics

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer

MAPS and Wesana Health Resume Negotiations

Field Trip Launches Site Management Organization (SMO) Services, Hires Stéphan Côté...

MindMed Appoints Robert Barrow as Chief Executive Officer and Director

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial...

HAVN Life Successfully Exports Psilocybin from Jamaica Facility into the U.S....

atai Life Sciences Has Been Selected for Addition to the NASDAQ...

Lobe Sciences Announces That Its Shares Will Trade on the OTCQB(R)...

PharmaDrug Announces Addition of Dr. Cindy Hutnik, President of the Canadian...

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as...

1...200201202...305 Page 201 of 305

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts...

Manvir Singh: Shamanism, the Timeless Religion

2025 Year in Review: Future(s) & Open Questions (Video)

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

ABOUT US

PsyNews.com has a single-sector focus. We are a news platform dedicated to covering the psychedelic industry. This includes companies, startups, venture capital firms, investment banks, pharma, research, etc, anything associated with the new emerging industry and asset class. Many of the chemicals and compounds involved are LSD, psilocybin, DMT, ketamine, MDMA, ecstasy, ibogaine, analogs, derivatives, psychedelic mushrooms, fungi, psilocin, entheogens, empathogens, indocybin, magic truffles (psilocybin sclerotia), etc. They range from classical and standard to new and exotic. PsyNews.com will cover all psychedelic news in the psy industry, including current events, updates, and what’s happening everywhere in the sector in term of developments and investments. We will be tracking companies worth, valuation, ROI, financials, stock, revenue, IPO’s, and more. Along with medical, recreational, clinical trials, FDA, mindfulness, psy space, 5-HT2A receptor experiments, and so forth. Join us on an unforgettable journey to the center of the psychedelic industry.

Featured

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts Hold on GH Research’s 5-MeO-DMT IND; Compass Details Pivotal PTSD Trial Design; Cybin...

Manvir Singh: Shamanism, the Timeless Religion

2025 Year in Review: Future(s) & Open Questions (Video)

2025 Year in Review: 10 Standout Stories in Psychedelics

2025 Year in Review: Looking Ahead to Psychedelics in 2026 (Video)

MINDCURE Appoints Dr. Doron Sagman as Chief Medical Officer

MAPS and Wesana Health Resume Negotiations

Field Trip Launches Site Management Organization (SMO) Services, Hires Stéphan Côté...

MindMed Appoints Robert Barrow as Chief Executive Officer and Director

atai Life Sciences Announces Successful Outcome of Phase 2a Biomarker Trial...

HAVN Life Successfully Exports Psilocybin from Jamaica Facility into the U.S....

atai Life Sciences Has Been Selected for Addition to the NASDAQ...

Lobe Sciences Announces That Its Shares Will Trade on the OTCQB(R)...

PharmaDrug Announces Addition of Dr. Cindy Hutnik, President of the Canadian...

COMPASS Pathways announces positive outcome of 25mg COMP360 psilocybin therapy as...

EDITOR PICKS

Pα+ Psychedelic Bulletin #217: Gilgamesh’s GM-1020 Prints Positive Topline; FDA Lifts...

Manvir Singh: Shamanism, the Timeless Religion

2025 Year in Review: Future(s) & Open Questions (Video)

POPULAR POSTS

How to Get DMT: Obtaining the Spirit Molecule

Having Sex on DMT: What You Need to Know

DMT Pricing Guide

POPULAR CATEGORY